24 January 2023
Exposure to World Trade Center Dust Exacerbates Cognitive Impairment in an Animal Model of Alzheimer’s
Mice exposed to World Trade Center dust exhibit a significant impairment in spatial recognition and short- and long-term memory, as well as changes in genes related to immune-inflammatory responses and blood-brain barrier disruption, according to a study conducted by researchers from the Icahn School of Medicine at Mount Sinai and published January 17 in the Journal of Alzheimer’s Disease.
22 December 2022
Middle-aged smokers are far more likely to report having memory loss and confusion than nonsmokers, and the likelihood of cognitive decline is lower for those who have quit, even recently, a new study has found. The research from The Ohio State University is the first to examine the relationship between smoking and cognitive decline using a one-question self-assessment asking people if they’ve experienced worsening or more frequent memory loss and/or confusion.
22 December 2022
Dementia is on the rise in Germany. In the absence of treatment options, the focus is shifting to preventing dementia. In particular, a healthy lifestyle is considered beneficial for brain health. A study by the Faculty of Medicine now shows that opportunities for a healthy lifestyle are unequally distributed: being socially disadvantaged is associated with a higher risk of dementia. The current findings have been published in the Journal of Alzheimer’s Disease.
20 December 2022
Dementia Was Associated with COVID-19 Mortality, but the Association Was Weaker Than in Previously Published Studies
Since December 2019, more than 60 million people have been diagnosed with coronavirus disease 2019 (COVID-19) worldwide, while approximately six million individuals have died as a result of the disease. Hospital treatment was required in about 10%–20% of COVID-19 patients, with this proportion decreasing over time. Several studies have shown the impact of dementia on mortality in COVID-19 patients, however, most studies were conducted during the first months of the COVID-19 pandemic.
20 December 2022
Results from a clinical research study co-authored by physicians and scientists at the Pacific Neuroscience Institute (PNI) at Providence Saint John’s Health Center indicate a correlation between two modifiable risk factors – muscular strength and mobility – and brain atrophy among persons with Alzheimer’s disease.
19 December 2022
A recent study from the University of Eastern Finland shows that previous traumatic brain injury may potentially affect the risk of frontotemporal dementia (FTD), especially in patients who did not carry a causal genetic mutation. In addition, patients who had suffered a head injury appeared, on average, to develop FTD earlier than others. The researchers compared Finnish FTD patients with patients with Alzheimer’s disease, and with healthy controls.
29 November 2022
When the U.S. Food and Drug Administration gave controversial accelerated approval to the first Alzheimer’s drug in nearly 20 years, it had a surprising impact on attitudes about research into the disease. A survey by University of California, Irvine neuroscientists has found news coverage of the FDA’s decision made the public less willing to volunteer for Alzheimer’s pharmaceutical trials. The study was conducted by the UCI Institute for Memory Impairments and Neurological Disorders, known as UCI MIND.
16 November 2022
In a Commentary published in JAD, authors Poul F. Høilund-Carlsen, Mona-Elisabeth Revheim, Abass Alavi , Nagichettiar Satyamurthy, and Jorge R. Barrio have detailed their views questioning the amyloid hypothesis that has dominated Alzheimer research and treatment trials for 30 years. In particular they question the use of amyloid-PET scanning, an imaging procedure that has been used to show whether new therapies are able to reduce cerebral amyloid deposits as this is assumed to inhibit the development of Alzheimer's disease. They contend that this very finding contributed to the FDA’s approval of Aduhelm contrary to its own independent expert panel which looked in vain for evidence of a favorable clinical effect.
2 November 2022
Stigma, depressive symptoms and feelings of hopelessness are common problems in the early stages of Alzheimer's disease (AD). A recent study conducted at 21 memory clinics in Spain, published in the Journal of Alzheimer's Disease, has found that different psychological problems negatively impact patients' quality of life even in a population with a short disease duration and minimal cognitive impairment.
20 October 2022
New research from Qatar University College of Health Sciences (QU-CHS) and the School of Nursing at the University of Pennsylvania has found that higher tea intake is associated with reduced cognitive decline in adults. Dementia is known to affect the quality of life, while cognition-related disorders such as mild cognitive impairment and Alzheimer’s disease are gradually increasing and becoming a global burden. This study, published in the Journal of Alzheimer’s Disease, may shed light on the potential role of tea consumption in preventing cognitive decline.